Inflammatory bowel disease (IBD) is a chronic, non-specific inflammatory condition characterized by recurring inflammation of the intestinal mucosa. However, the existing IBD treatments are ineffective and have serious side effects. The etiology of IBD is multifactorial and encompasses immune, genetic, environmental, dietary, and microbial factors.
A variety of nanoparticle types have been employed as drug carriers for the treatment of inflammatory bowel disease (IBD), with encouraging outcomes observed in experimental models [1]. They increase the bioavailability of drugs and enable targeted drug delivery, promoting localized treatment and thus enhancing efficacy. Nevertheless, numerous challenges persist in the translation from nanomedicine to clinical application, including enhanced formulations and preparation techniques, enhanced drug safety profiles, and so forth.
This review paper mentions a CD-related example: Zhang et al produced NPs (Tpl/OxbCD NP) by encapsulating the free radical scavenger Tempol (Tpl) in oxidation-responsive b-cyclodextrin, which releases cargo molecules by scavenging ROS components. A hydrogen peroxide-eliminating CD derivative (OxbCD) was synthesized by functionalization of β-CD with an oxidation-labile moiety of 4-(hydroxymethyl) phenylboronic acid pinacol ester (PBAP). According to drug imaging, OxbCD NPs had a higher targeting effectiveness than control PLGA NPs and accumulated 2.5 times more fluorescence intensity in mouse colon tissue than in normal mice. The oral Tpl/OxbCD NPs group showed a significant reduction in symptoms in three mice colitis models, with more efficacy than the free radical scavenger Tpl and -based control nanomedicine.[2]
See also:
[1] Gao J, Li J, Luo Z, Wang H, Ma Z. Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment. Drug Des Devel Ther. 2024;18:2921-2949
https://doi.org/10.2147/DDDT.S461977
[2] Zhang Q, Tao H, Lin Y, Hu Y, An H, Zhang D, Feng S, Hu H, Wang R, Li X, Zhang J. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials. 2016 Oct;105:206-221. doi: 10.1016/j.biomaterials.2016.08.010.